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Background: Rabbit antithymocyte globulin (rATG, Thymoglobulin®) is the most common induction immunosuppression
therapy in kidney transplantation. We applied a database integration strategy to capture and compare long-term
(10-year) outcome data for US participants in a clinical trial of rATG versus FDA-approved basiliximab.
Methods: Records for US participants in an international, 1-year, randomized clinical trial comparing rATG and
basiliximab induction in deceased donor kidney transplantation were integrated with records from the US
national Organ Procurement and Transplantation (OPTN) registry using center, transplant dates, recipient sex, and
birthdates. The OPTN captures center-reported acute rejection, graft failure, death, and cancer events, and
incorporates comprehensive death records from the Social Security Death Master File. Ten-year outcomes
according to randomized induction regimen were compared by Kaplan–Meier analysis (two-sided P).
Non-inferiority of rATG was assessed using a one-tailed equivalence test (a-priori equivalence margins of 0–10 %).
Results: Of 183 US trial participants, 89 % (n = 163) matched OPTN records exactly; the remainder were matched
by extending agreement windows for transplant and birthdates. Matches were validated by donor and recipient
blood types. By Kaplan–Meier analysis, 10 years post-transplant, freedom from acute rejection, graft failure, or death
was 32.6 % and 24.0 % in the rATG and basiliximab arms, respectively (P = 0.09). The incidence of acute rejection
with rATG versus basiliximab induction was 21.0 % versus 32.8 % (P = 0.07). Patient survival (52.8 % versus 52.2 %,
P = 0.92) and graft survival (34.3 % versus 30.9 %, P = 0.56) rates were numerically and statistically similar for both
arms. Comparison of the composite outcome meets non-inferiority criteria even with a 0 % equivalence margin
(one-sided P = 0.04). With a 10 % equivalence margin, the odds that rATG is no worse than basiliximab for 10-year risk
of the composite endpoint are >99 %.
Conclusions: Ten years post-transplant, rATG induction has comparable efficacy and safety to FDA-approved
basiliximab. Integration of clinical trial records with national registry data can enable long-term monitoring of trial
participants in transplantation, circumventing logistical and cost barriers of extended follow-up.
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Antibody induction therapy in kidney transplantation is
highly effective in reducing acute rejection [1] and,
ultimately, in preserving allograft function [2]. Use of in-
duction agents has increased over recent years such that,
by 2013, more than 89 % of kidney transplants in the
USA were performed with induction therapy [3]. Not-
ably, while rabbit antithymocyte globulin (rATG) is the
most commonly used induction agent in contemporary
kidney transplantation [3, 4], it was approved by the US
Food and Drug Administration (FDA) in 1998 for the
treatment of acute rejection but not for the prevention
of rejection (induction) [5]. To date only basiliximab and
daclizumab, both antibodies against the inter-leukin-2
receptor (IL2R Abs), have been approved by the FDA for
use as induction agents in kidney transplantation, and
daclizumab is no longer marketed.
A pivotal component of the evidence base informing
current understanding of the effectiveness of alternative
induction regimens in kidney transplantation came from
the 10-10 Study, which was the first prospective, ran-
domized, international clinical trial comparing rATG
and basiliximab among deceased donor transplant recip-
ients perceived to be at increased risk of acute rejection
or delayed graft function (defined as the need for dialysis
within 7 days of transplantation) [6]. The 278 trial par-
ticipants included 183 patients enrolled at 17 US cen-
ters; participants received cyclosporine, mycophenolate
mofetil, and prednisone for maintenance immunosup-
pression. The 12-month study demonstrated that both
induction agents were equally effective (P = 0.34) in
preventing the composite quadruple endpoint of acute
rejection, delayed graft function, graft loss, or death.
However, when analyzed as a more traditional FDA
endpoint of acute rejection, graft failure, or death, the
differences were statistically significant in favor of
rATG (P = 0.02), driven by a lower acute rejection rate
in the rATG group (15.6 % versus 25.5 %, P = 0.02) [6].
The duration of follow-up in clinical trials is limited
by the willingness of patients to participate for extended
periods as well as by the ability of investigators to com-
mit the time and resources necessary to track and moni-
tor participants over a number of years. Extended
monitoring beyond an initially determined study period
may require additional informed consent and always in-
curs added costs. Consequently, long-term safety and ef-
ficacy data are lacking for many drugs in multiple
treatment domains, including transplantation [7]. Thus,
there is a need for approaches to assessing long-term
outcomes for non-FDA-approved drug uses.
Solid organ transplantation is unique among medical
specialties in the universal collection of clinical data in
national registries in some countries. In the USA,
through the mechanism of the Organ Procurement andTransplantation Network (OPTN), as mandated by the
National Organ Transplant Act, transplant centers have
been required to submit baseline and follow-up clinical
data describing all patients listed for and receiving solid
organ transplants since 1987 [8]. The OPTN supplements
program-reported outcomes information with data from a
national death registry, providing a high level of accuracy
for the ascertainment of patient and allograft survival [9].
However, owing to a lack of granularity in the collection
of baseline information relevant to eligibility and balanced
comparisons as required within a clinical trial framework,
it has been difficult to draw unbiased inferences on the
long-term efficacy and safety of different immunosuppres-
sive regimens based on registry data alone.
Integration of clinical trial and transplant registry re-
cords may circumvent some of the logistical difficulties
in conducting long-term clinical studies and the limita-
tions of isolated registry analyses. However, despite the
opportunity created by the presence of national trans-
plant registries, examples of the use of this approach in
transplantation are limited. We previously linked data
from the 10-10 Study with OPTN records to assess 5-
year clinical outcomes of US-enrolled participants and
found that patients treated with rATG had a lower inci-
dence of a traditional composite endpoint of acute rejec-
tion, graft failure or death (37 % versus 51 %, P = 0.04)
[10]. Using a similar approach, 15-year follow-up of 133
Australian participants in the Tricontinental Mycophe-
nolate Mofetil Renal Transplantation Study was recently
successfully achieved by linking trial records with
follow-up reports from the Australia and New Zealand
Dialysis and Transplant Registry (ANZDATA) [11].
Ten years have now passed since completion of enroll-
ment in the rATG versus basiliximab induction immuno-
suppression trial. The goal of the current study was to link
records for US participants in the 10-10 Study with
current OPTN follow-up records to compare long-term
efficacy and safety over 10 years after transplantation.
Methods
Data sources and sampling
Clinical trial data were obtained from a randomized, multi-
center international trial involving 278 kidney transplant re-
cipients in the USA and Europe (the 10-10 Study, Clinical-
Trials.gov NCT00235300) [6]. The clinical trial compared
1-year post-transplant outcomes after treatment with rATG
(n = 141) or basiliximab (n = 137) as part of immunosup-
pression regimens in deceased donor renal allograft recipi-
ents. In all, 66 % of total participants (n = 183) were
enrolled at 17 US centers between May 2000 and March
2002. Patient eligibility for trial enrollment was based on
prolonged cold ischemia times and donor and recipient risk
factors for acute rejection, or delayed graft function, as pre-
viously described [6].
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trial participants were obtained from OPTN registry data.
As mandated by the National Organ Transplant Act, the
OPTN collects information on all solid organ transplant
recipients and donors in the USA as submitted by OPTN
member centers, including transplant date and baseline
demographic and clinical information. Post-transplant
follow-up information is collected 6 months after trans-
plant, on the first transplant anniversary, and then annu-
ally. Center-reported death records are supplemented
within the OPTN registry by the national Social Security
Death Master File (SSDMF). The Health Resources and
Services Administration (HRSA), of the US Department
of Health and Human Services, provides oversight to
the activities of the OPTN contractor.
Corresponding OPTN records for trial participants
were first sought using transplant center, sex, and exact
recorded dates of transplantation and birth in each data
source. As the available trial records provided dates of
administration of anesthesia for transplant surgery and
transplant surgery may occur overnight, OPTN records
for trial participants who were not exactly matched ini-
tially were sought using trial-reported surgical anesthesia
dates ± 1 day. To account for transcription errors,
matches were identified for remaining patients using age
instead of month and day of birth, or transplant year in-
stead of month and day of transplant. Final matches
were validated by comparing trial versus OPTN reports
of donor and recipient ABO blood types.
Approvals
This study was approved by the Saint Louis University
Institutional Review Board (protocol number 23175),
and by OPTN/HRSA. Because of the anonymity of the
patients studied, and the non-intrusive nature of the
current research using previously collected records without
patient contacts, a waiver of informed consent was granted
per the Department of Health and Human Services Code
of Federal Regulations (Title 45, Part 46, Paragraph
46.116). Analyses were performed using limited datasets,
compliant with the US Health Information Portability and
Accountability Act.
Treatment regimens in the randomized trial
Immunosuppression treatment regimens and regimen
allocation used in the randomized trial have been reported
previously [6]. Briefly, eligible, enrolled participants were
randomized (1:1) to receive either rATG (Thymoglobulin®,
Genzyme, Cambridge, MA) a lymphocyte-depleting poly-
clonal antibody targeting multiple immunologic epitopes,
or basiliximab (Simulect®, Novartis Pharmaceuticals) a
non-lymphocyte-depleting monoclonal antibody targeting
the interleukin-2 receptor for induction immunosuppres-
sion. rATG was administered at 1.5 mg per kg of bodyweight per day intravenously for a total target dose of 7.5
mg per kg of body weight. The first dose was administered
intra-operatively prior to graft reperfusion. Basiliximab
was administered at 20 mg intravenously on the day of
transplant prior to graft reperfusion and on day 4 post-
transplant. All patients received cyclosporine (modified),
mycophenolate mofetil, and prednisone. Mycophenolate
mofetil was initiated prior to transplantation, and the
initial dose of cyclosporine was administered by day 4.
Investigators used corticosteroid tapering to reduce
prednisone to 5 mg per day by 6 months or earlier.
Appropriate infection prophylaxis was mandated by
the study protocol, as described previously [6].
Outcomes and ascertainment
The 10-year primary efficacy endpoint was the FDA-
specified composite triple endpoint of allograft rejection,
graft failure, or patient death used in clinical trials of
immunosuppression efficacy. Secondary endpoints included
acute rejection, death-censored graft failure, and all-cause
graft loss, evaluated individually at 10 years post-transplant.
Trial-reported events within the 1-year trial period were
supplemented with OPTN records to ascertain long-term
outcomes. The OPTN queries centers for information on
acute rejection according to periods covered by specific
reporting forms (0 to 6 months, 7 to 12 months, then
annual periods), but dates of acute rejection within report-
ing periods are not collected. We defined acute rejection
from OPTN records according to center reports that an
acute rejection event occurred, taking the event date as the
follow-up record date, as per prior methods for identifying
acute rejection from OPTN registry data [12, 13]. Acute
rejection as a cause of graft failure was included.
Mortality was defined as date of death from any cause,
as reported within the trial or from OPTN records based
on transplant center or the SSDMF reports. Ascertain-
ment of death, including national death registry SSDMF
records, was considered complete. Graft failure was de-
fined as the earliest reported date of return to mainten-
ance dialysis or ‘preemptive’ re-transplantation. Times to
acute rejection, graft failure, and the composite triple
endpoint were right censored at 10 years post-transplant
or center-reported loss-to-follow-up.
Renal function at annual follow-up was quantified as es-
timated glomerular filtration rate according to the abbrevi-
ated Modification of Diet in Renal Disease equation [14].
Serum creatinine values were drawn from OPTN recipient
follow-up reporting forms, and age for glomerular filtra-
tion rate estimation was computed as age at follow-up.
Diagnoses of malignancy, as captured in the trial re-
ports for up to 1 year post-transplant and by OPTN
follow-up reports to 10 years, were examined as a safety
endpoint. Time-to-malignancy was computed as the
time to the date of first reported cancer diagnosis, and
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transplant lymphoproliferative disorder, non-melanoma
skin cancer or other cancer diagnosis.
Statistical analyses
Data management and analyses were performed with
SAS for Windows software, version 9.3 (SAS Institute
Inc., Cary, NC). Distributions of baseline recipient, donor,
and transplant factors according to induction treatment
assignment, including missing values, were compared
using Fisher’s exact test for categorical factors and the
Wilcoxon–Mann–Whitney test or the t test for continu-
ous variables, as previously reported [6, 10]. No imput-
ation for missing data was performed. The Kaplan–Meier
method was used to estimate the frequencies of acute re-
jection, graft failure, death, or cancer, as well as the pri-
mary composite endpoint, at 10 years post-transplant, and
the log rank test was applied to compare differences in
event frequencies according to induction regimen using a
2-sided P-value, to assess superiority. The primary ana-
lyses compared outcomes at 10 years post-transplant.
Non-inferiority of rATG compared with FDA-approved
basiliximab for the composite outcome was assessed using
a one-tailed equivalence test with α equal to 0.05 and
a-priori defined equivalence margins of 0 % and 10 % [15].
As the prior 5-year linkage study used data extracted
shortly after 5 years after trial enrollment [10], and be-
cause the OPTN registry incorporates events attributable
to prior periods if newly reported by centers after anFig. 1 Schematic of data linking procedures and resulting patient matches. DOannual survey, we also re-analyzed 5-year outcomes in the
recently extracted data as a secondary analysis. Estimated
glomerular filtration rate among survivors with graft func-
tion in the two treatment groups was compared at each
annual follow-up time by t tests.
Results
Matching US trial and OPTN registry records
Results of the procedures for identifying OPTN reports for
US-enrolled trial participants are shown in Fig. 1. A total of
89 % (n = 163) of patients were exactly matched in both
data sources using center, transplant date, sex, race, and
date of birth. Recorded transplant surgery or anesthesia
dates varied within ± 1 day for 13 patients (7.1 %) who
matched exactly on other parameters. Five (2.7 %) patients
were matched using age instead of month and day of birth,
along with exact matching for the other parameters. Finally,
one (0.5 %) patient was matched using transplant year
instead of transplant date and one (0.5 %) final match was
identified using age and transplant year along with sex and
transplant center. The final 183 matches were validated by
recipient and donor ABO types in the trial and OPTN re-
cords. Additional file 1 displays the percentage agreement
of trial and OPTN records for the matching and validation
variables.
Patient characteristics
As previously reported, 91 of the 183 US participants were
randomized to receive rATG induction in the clinical trialB, date of birth; OPTN, Organ Procurement and Transplantation Network
Table 2 Clinical outcomes among US-enrolled induction
therapy trial participants based on integrated trial records
and OPTN follow-up data
rATG % Basiliximab % P
Outcomes at 1 year
Acute rejection 14.3 % 22.8 % 0.08
Patient survival 94.5 % 95.7 % 0.74
All-cause graft survival 89.0 % 85.9 % 0.47
Freedom from acute rejection,
graft failure or death
80.0 % 68.5 % 0.04




Non-melanoma skin cancer 1.1 % 0 0.31
Non-skin cancer 0 1.1 % 0.32
Outcomes at 5 years
Acute rejection 21.0 % 32.8 % 0.07
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recipient and donor characteristics were complete except
for cold ischemia time, for which the distribution of miss-
ing values was similar across the treatment arms (Table 1).
Baseline characteristics were similar among US partici-
pants in the two induction groups (Table 1), as previously
summarized [10].
Acute rejection, graft survival, and patient survival
US participants randomized to receive rATG had higher
freedom from the triple endpoint of rejection, graft
failure, or death at 1 year post-transplant (80.0 % versus
68.5 %, two-sided P = 0.04) (Table 2). Similar to results
detected using OPTN records previously extracted in
2007 [10], significantly higher freedom from the com-
posite endpoint at 5 years post-transplant in the rATG
versus basiliximab arm was replicated using the current,
updated data (57.6 % versus 44.2 %, 2-sided P = 0.04).Table 1 Baseline characteristics of US-enrolled participants in







Age (years), mean ± standard
deviation
49.6 ± 12.4 49.0 ± 13.0 0.73
Male, % 58 % 65 % 0.36
Race, %: 0.29
White 40 % 53 %
Black 45 % 40 %
Other 15 % 8 %
Peak panel-reactive antibody level,
mean ± standard deviation
18.7 ± 31.8 17.7 ± 30.7 0.83
Donor characteristics
Age (years), mean ± standard deviation 42.9 ± 16.3 43.4 ± 17.7 0.84
Donors older than 50 years, % 44 % 47 % 0.77
Male, % 49 % 58 % 0.30
Race, %: 0.80
White 79 % 80 %
Black 12 % 10 %
Other 9 % 10 %
Donation after cardiac death, % 7 % 7 % 0.99
Diabetes mellitus, % 5 % 3 % 0.50
Hypertension, % 30 % 26 % 0.62
Transplant characteristics
Cold ischemia time (hours),
mean ± standard deviation
25.7 ± 9.6 26.0 ± 8.4 0.82
Missing, % 8.8 % 7.6 % 0.77
Previous transplantation, % 5 % 5 % 1.00
From: N Engl J Med, Brennan DC and Schnitzler MA, Long-Term Results of
Rabbit Antithymocyte Globulin and Basiliximab Induction, Volume 359, Pages
1736–8, 2008. Massachusetts Medical Society [10]. Reprinted with permission
Patient survival 72.5 % 75.0 % 0.64
All-cause graft survival 67.5 % 60.6 % 0.32
Freedom from acute rejection,
graft failure, or death
57.6 % 44.2 % 0.04
Any malignancy 4.5 % 4.5 % 0.97
Post-transplant lymphoproliferative
disorder
1.1 % 0 0.31
Non-melanoma skin cancer 2.3 % 1.1 % 0.54
Non-skin cancer 2.3 % 3.3 % 0.67
Outcomes at 10 years
Acute rejection 21.0 % 32.8 % 0.07
Patient survival 52.8 % 52.2 % 0.92
All-cause graft survival 34.3 % 30.9 % 0.56
Freedom from acute rejection,
graft failure, or death
32.6 % 24.0 % 0.09
Any malignancy 9.5 % 8.1 % 0.75
Post-transplant lymphoproliferative
disorder
2.2 % 0 0.15
Non-melanoma skin cancer 3.6 % 1.1 % 0.30
Non-skin cancer 6.0 % 6.9 % 0.79By Kaplan–Meier analysis, at 10 years post-transplant,
freedom from a composite of acute rejection, graft
failure or death was 32.6 % and 24.0 % in the rATG
and basiliximab arms, respectively (two-sided P = 0.09)
(Fig. 2). Comparison of the composite outcome meets
non-inferiority criteria even with a 0 % equivalence mar-
gin (one-sided P = 0.04). With a typical 10 % equivalence
margin, the odds that rATG is no worse than basilixi-
mab for 10-year risk of the composite endpoint are
greater than 99 % based on the results of this study.
At 1 year, patients treated with rATG had a non-
significant trend towards lower acute rejection incidence
(14.3 % versus 22.8 %, two-sided P = 0.08) (Table 2). At 5
Fig. 2 Freedom from triple endpoint according to induction
regimen. Basi, basiliximab; rATG, rabbit antithymocyte globulin
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jection trended lower among patients randomized to rATG
compared with basiliximab, but did not reach significance
(21.0 % versus 32.8 %, respectively, two-sided P = 0.07). No
patients developed incident registry-reported rejection
events after 5 years, such that the 10-year incidence of
acute rejection was also 21.0 % in the rATG arm and
32.8 % in the basiliximab arm (two-sided P = 0.07) (Fig. 3a).
Death-censored graft survival was also equivalent in the
two groups by 10 years (rATG, 68.5 %; basiliximab, 68.4
%; two-sided P = 0.80) (Fig. 3b). Patient survival was nu-
merically and statistically similar in both treatment groups
at 5 years and equivalent at 10 years (rATG, 52.8 %; basi-
liximab, 52.2 %; P = 0.92) (Fig. 3c). Combining trends in
mortality and graft failure, all-cause graft survival was gen-
erally similar over time among participants randomized to
both trial arms, and by 10 years was 34.3 % in those
treated with rATG versus 30.9 % in those treated with
basiliximab (two-sided P = 0.56) (Fig. 3d).
Renal function
Estimated glomerular filtration rate was computed at
each annual follow-up time among patients with a re-
ported serum creatinine value on corresponding OPTN
follow-up forms. An additional file summarizes causes of
missing serum creatinine values, including graft loss,
death, or missed reporting (Additional file 2). The fre-
quency of missed reporting did not differ by treatment
group at any follow-up point. Subject counts for glom-
erular filtration rate estimation declined from 78 and 75
in the rATG and basiliximab arms, respectively, at 1 yearto 25 and 21, respectively, at 10 years. Among survivors
with graft function and available serum creatinine values
at each follow-up year, mean glomerular filtration rate
was similar in participants in the two trial arms (Fig. 4).
Malignancy
The cumulative incidence of any cancer by 10 years
post-transplant was similar (P = 0.75) among patients
who received rATG or basiliximab in the trial, at 9.5 %
and 8.1 %, respectively. The 10-year incidences of skin
cancer (3.6 % versus 1.1 %, P = 0.30), post-transplant
lymphoproliferative disorder (2.2 % versus 0 %, P = 0.15)
and other cancers (6.0 % versus 6.9 %, P = 0.79) also did
not differ significantly among patients randomized to
rATG compared with basiliximab (Table 2).
Discussion
Results from the first prospective, randomized, multi-
center clinical trial comparing the two leading antibody
induction agents in renal transplantation, known as the
10-10 Study, provided valuable information on the
short-term safety and efficacy of these induction agents
[6]. However, information on long-term outcomes asso-
ciated with initial choice of antibody induction agent is
lacking. We integrated clinical trial records for the US
participants in the 10-10 Study with current OPTN
follow-up records to compare long-term efficacy and
safety over 10 years after transplantation.
In the current analysis, we found that patients treated
with rATG had similar long-term patient and graft sur-
vival at 10 years post-transplant as patients treated with
the FDA-approved induction agent basiliximab. Congru-
ent with previously observed superiority of rATG versus
basiliximab induction for the FDA-specified composite
triple endpoint of allograft rejection, graft failure or pa-
tient death used in clinical trials of immunosuppression
efficacy observed at 1 year post-transplant [6, 10], super-
iority with rATG induction for this composite endpoint
was confirmed at 5 years using current data for this
US-based sub-analyses. At 10 years post-transplant, while
freedom from the composite of acute rejection, graft fail-
ure or death was not significantly different among US par-
ticipants in the two trial arms, non-inferiority for rATG
compared with FDA-approved basiliximab for 10-year risk
of the composite endpoint was demonstrated with a high
level of statistical certainty.
Because rATG is a more potent induction agent than
IL2R Abs, there is concern over increased risks of death
and malignancy in the long-term. We found that there
were no significant differences in these outcomes at 10
years. Although our observations contradict prior re-
ports raising concern for more common post-transplant
malignancies with rATG [16, 17], there were numerically
higher point estimates of lymphoproliferative disorder
Fig. 3 10-year outcomes according to induction regimen. a Freedom from acute rejection. b Death-censored graft survival. c Patient survival.
d All-cause graft survival. Basi, basiliximab; rATG, rabbit antithymocyte globulin
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cancer, in the rATG arm, and the lack of significance
may be impacted by the low study power. Continued as-
sessment of the impact of induction immunosuppression
on cancer risk is warranted. Importantly, the close align-
ment of the patient survival curves and very similar
magnitude of the 10-year survival fractions supports
truly equivalent long-term survival. A strength of the
current analysis is that we studied a carefully characterized
patient sample with confirmed induction exposure, and
linked to long-term transplant registry data for outcomes
ascertainment, including comprehensive national death
records. We did not assess early complications aside from
those captured as study outcomes in the current analysis.
Common concerns with the use of rATG early after trans-
plantation include thrombocytopenia, leucopenia, pyrexia,
and hypotension. We previously reported associations of
rATG with transient thrombocytopenia and leucopenia
(driven by lymphopenia) that resolved by post-operative
day 14 [6].Maintenance immunosuppression warrants consider-
ation in any study of induction therapies. Cyclosporine,
mycophenolate, and low-dose prednisone were used in
the 10-10 Study. While the most common maintenance
immunosuppression regimen in current US practice is
tacrolimus, mycophenolate, and low-dose prednisone,
cyclosporine continues to be used as the primary cal-
cineurin inhibitor among many patients internationally.
A subsequent randomized comparison of rATG versus
the IL2R Ab daclizumab in the context of maintenance
tacrolimus, mycophenolate, and low-dose prednisone
among high immunologic-risk patients showed that
rATG induction was associated with lower rates of de-
layed graft function (32 % versus 45 %, P = 0.04), acute
rejection (15 % versus 27 %, P = 0.02), and need for anti-
lymphocyte treatment of acute rejection (2.7 % versus
14.9 %, P = 0.002) at 1 year post-transplant [18]. This
benefit of rATG in lowering acute rejection compared
with an IL2R Ab was nearly identical to the benefit seen
in the 10-10 Study, despite the use of tacrolimus as the
Fig. 4 Estimated glomerular filtration rate by trial arm at each annual follow-up time (years post-transplant) among patients with a reported
serum creatinine value on corresponding OPTN follow-up forms. Basi, basiliximab; eGFR, estimated glomerular filtration rate; rATG, rabbit
antithymocyte globulin
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open-label trial comparing rATG versus dacluzimab or
basiliximab, also in the context of maintenance tacroli-
mus, mycophenolate, and corticosteroids, found that
only rATG was protective against 6-month and 1-year
acute rejection in African-American recipients [19]. Fi-
nally, our analysis considered maintenance therapy from
an intention-to-treat perspective, but it is possible that
maintenance regimens changed over time.
There are other limitations to our study. We were un-
able to capture follow-up data for the European patients
enrolled in the original trial, owing to use of a US-based
transplant registry. No similar comprehensive registry
existed in the participating European countries at the
time of the trial. As a result, 34 % of the initial sample
was not included in the current analysis, compromising
statistical power. Although 96 % of trial and OPTN re-
cords matched exactly on all linkage parameters or with
±1 day extension of transplant date (to account for dif-
ferences in recorded anesthesia induction versus trans-
plant date in the two sources), 4 % of matches required
broadening of agreement windows for transplant or
birthdates, and thus indicate recording errors for these
dates in one of the sources; such recording errors cannotbe resolved with the current design based on extracted
information without direct access to center records. Ob-
served baseline characteristics were well balanced across
the included subjects in the two treatment arms, but im-
balances in unmeasured characteristics are possible.
While the intervention of interest, induction immuno-
suppression, is solely an early exposure, loss of blinding
after the completion of the trial and subsequent unmeas-
ured impacts on other aspects of care is also a potential
limitation of the study design.
The long-term data presented were also limited by the
fields captured in the OPTN registry. For example,
histological assessments of the type and severity of acute
rejection episodes are not collected by the OPTN. Al-
though center-reported death records were supple-
mented with the SSDMF and thus considered to be
complete, outcomes (acute rejection, graft failure) that
relied solely on center reports could be incompletely
captured. Because the OPTN registry incorporates
events attributable to prior periods if newly reported by
centers after an annual survey, we also re-analyzed 5-
year outcomes in the recently extracted data and found
slightly higher event rates compared with the prior 2007
extraction [10] but with very consistent patterns. It is
Lentine et al. Trials  (2015) 16:365 Page 9 of 10possible that re-extraction after a longer latency could
also impact estimates of 10-year event frequencies if
some events close to the end of the study period were
recognized and reported after our data extraction.
Conducting clinical trials with long-term follow-up
poses many challenges, from financial burdens to the
unwillingness of patients, physicians, and commercial
and academic sponsors to participate in studies that re-
quire years of involvement. Consequently, long-term
safety and efficacy data are lacking for most drugs [20].
Although post-marketing surveillance for adverse effects
is mandatory by the FDA, the success of such programs
relies heavily on spontaneous reporting by healthcare
providers. In the field of transplantation in particular, al-
though the majority of contemporary immunosuppres-
sive agents have been used in clinical practice for
decades, there are few long-term, prospective clinical tri-
als evaluating safety and efficacy [21–25]; hence, the op-
timal immunosuppressive regimen remains a subject of
debate. Here, we describe an efficient, non-obtrusive
method of monitoring long-term treatment outcomes
using the combination of a properly designed clinical
trial and registry outcomes data. Our data integration
approach could be particularly useful in addressing other
uncertainties for immunosuppression-related outcomes
in transplantation when clinical trial and registry data
are available. Despite the opportunity created by the
presence of national transplant registries, we are aware
of only two prior demonstrations of this approach in
transplantation: a 5-year follow-up of the 10-10 Study by
our group [10], and linkage of records from a mainten-
ance immunosuppression trial with ANZDATA records
[11]. We believe this methodology has potential for
more common application in the field of transplantation,
as well as broader implications for other fields with ac-
cess to both trial and registry data.
Conclusions
In summary, integrating records from a clinical trial of
induction immunosuppression therapies with national
transplant registry data enabled ascertainment of long-
term follow-up information for 9 years beyond the dur-
ation of the original comparative trial. We found that,
compared with an FDA-approved induction agent, the
benefits of polyclonal induction with rATG for an FDA-
defined composite endpoint of acute rejection, graft
failure, or death were sustained through 5 years post-
transplant. At 10 years post-transplant, rATG induction
had comparable efficacy and safety to FDA-approved
basiliximab. Our methodology demonstrates an efficient
strategy for monitoring the long-term safety and efficacy
of therapies examined in clinical trials when registry data
for participants are also available. This approach may be
extended to clinical trials outside of transplantation.Additional files
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